BRIEF-J&J Announces Real-World-Evidence And Phase 3 Data Confirming Strong And Long-Lasting Protection Of Single-Shot Covid-19 Vaccine In The U.S

J&J: * J&J ANNOUNCES REAL-WORLD-EVIDENCE AND PHASE 3 DATA CONFIRMING STRONG AND LONG-LASTING PROTECTION OF SINGLE-SHOT COVID-19 VACCINE IN THE U.S

* J&J - SAFETY PROFILE OF COVID-19 VACCINE REMAINED CONSISTENT, WAS GENERALLY WELL TOLERATED WHEN ADMINISTERED AS A BOOSTER * J&J - AGAINST SYMPTOMATIC (MODERATE TO SEVERE/CRITICAL) COVID-19, BOOSTER SHOT AT 2 MONTHS PROVIDED 94% PROTECTION IN U.S., 75% PROTECTION GLOBALLY

* J&J - BOOSTER SHOT AT TWO MONTHS PROVIDED 100% PROTECTION AGAINST SEVERE/CRITICAL COVID-19, AT LEAST 14 DAYS POST-FINAL VACCINATION * J&J - BOOSTER SHOT OF CO'S COVID-19 VACCINE AT SIX MONTHS PROVIDED 12-FOLD INCREASE IN ANTIBODIES

* J&J - BOOSTER SHOT OF CO'S COVID-19 VACCINE AT TWO MONTHS PROVIDED FOUR TO SIX FOLD INCREASE IN ANTIBODIES * J&J - CO'S SINGLE-SHOT COVID-19 VACCINE SHOWED STRONG AND LONG-LASTING PROTECTION IN REAL WORLD EVIDENCE STUDY

* J&J - IN REAL-WORLD U.S. DATA, CO'S SINGLE-SHOT COVID-19 VACCINE SHOWED VACCINE EFFECTIVENESS OF 81% FOR COVID-19-RELATED HOSPITALIZATIONS * J&J - IN REAL-WORLD U.S. DATA, CO'S SINGLE-SHOT COVID-19 VACCINE SHOWED EFFECTIVENESS OF 79% FOR COVID-19 RELATED INFECTIONS

* J&J - PHASE 3 ENSEMBLE TRIAL OF SINGLE SHOT SHOWED 75% OVERALL EFFICACY AGAINST SEVERE/CRITICAL COVID-19, ACROSS ALL AGE COHORTS AND ALL COUNTRIES * J&J - IN U.S., PHASE 3 ENSEMBLE TRIAL OF SINGLE SHOT DEMONSTRATED 74% EFFICACY AGAINST SEVERE/CRITICAL INFECTION, 89% AGAINST HOSPITALIZATION

* J&J - IN U.S., PHASE 3 ENSEMBLE TRIAL OF SINGLE SHOT DEMONSTRATED 83% EFFICACY AGAINST COVID-19 RELATED DEATH Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)